^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Lovaxin C (axalimogene filolisbac)

    i
    Other names: ADXS11-001, Lm-LLO-E7, ADXS-HPV, ADXS-11-001, live attenuated listeria monocytogenes vaccine, Lm-Listeriolysin-O-fetal liver kinase-1, NSC-752718
    Associations

    News

    Trials
    Company:
    Ayala Pharma
    Drug class:
    Immunostimulant, HPV-16 E7 protein inhibitor
    Related drugs:
    Associations

    News

    Trials
    5ms
    A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy (clinicaltrials.gov)
    P2, N=0, Withdrawn, Advaxis, Inc. | N=124 --> 0 | Unknown status --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    pemetrexed • Lovaxin C (axalimogene filolisbac)
    4years
    [VIRTUAL] Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer (SGO-I 2020)
    The combination of durvalumab + ADXS11-001 appears to be safe and tolerable but requires close monitoring. The ORR was similar across arms, and the PFS in the durvalumab arm was numerically higher than that observed with durvalumab + ADXS11-001. Two objective responses were previously reported in subjects in part A, dose escalation of the study (ADXS11-001 at 1 × 109 CFU + MEDI 3 mg/kg, n = 4), including a complete response.
    P2 data • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • Lovaxin C (axalimogene filolisbac)
    over4years
    Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer (SGO 2020)
    The combination of durvalumab + ADXS11-001 appears to be safe and tolerable but requires close monitoring. The ORR was similar across arms, and the PFS in the durvalumab arm was numerically higher than that observed with durvalumab + ADXS11-001. Two objective responses were previously reported in subjects in part A, dose escalation of the study (ADXS11-001 at 1 × 109 CFU + MEDI 3 mg/kg, n = 4), including a complete response.
    P2 data • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • Lovaxin C (axalimogene filolisbac)
    over4years
    Phase II study of durvalumab alone or in combination with ADXS11-001 (AXAL) in recurrent/persistent or metastatic cervical cancer (SGO 2020)
    The combination of durvalumab + ADXS11-001 appears to be safe and tolerable but requires close monitoring. The ORR was similar across arms, and the PFS in the durvalumab arm was numerically higher than that observed with durvalumab + ADXS11-001. Two objective responses were previously reported in subjects in part A, dose escalation of the study (ADXS11-001 at 1 × 109 CFU + MEDI 3 mg/kg, n = 4), including a complete response.
    P2 data • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • Lovaxin C (axalimogene filolisbac)